195 related articles for article (PubMed ID: 10710174)
21. A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia.
Bakish D; Hooper CL; Filteau MJ; Charbonneau Y; Fraser G; West DL; Thibaudeau C; Raine D
Psychopharmacol Bull; 1996; 32(1):135-41. PubMed ID: 8927663
[TBL] [Abstract][Full Text] [Related]
22. Psychopathology of panic attacks in panic disorder.
Uhlenhuth EH; Leon AC; Matuzas W
J Affect Disord; 2006 May; 92(1):55-62. PubMed ID: 16448702
[TBL] [Abstract][Full Text] [Related]
23. [Panic disorder and agoraphobia: what is effective?].
Bandelow B; Sievert K; Röthemeyer M; Hajak G; Broocks A; Rüther E
Fortschr Neurol Psychiatr; 1995 Nov; 63(11):451-64. PubMed ID: 8575719
[TBL] [Abstract][Full Text] [Related]
24. Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia.
Mavissakalian MR; Perel JM
Arch Gen Psychiatry; 1999 Sep; 56(9):821-7. PubMed ID: 12884888
[TBL] [Abstract][Full Text] [Related]
25. Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships.
Mavissakalian MR; Perel JM
Am J Psychiatry; 1995 May; 152(5):673-82. PubMed ID: 7726306
[TBL] [Abstract][Full Text] [Related]
26. Relationship of panic, anticipatory anxiety, agoraphobia and global improvement in panic disorder with agoraphobia treated with alprazolam and exposure.
Başoğlu M; Marks IM; Kiliç C; Swinson RP; Noshirvani H; Kuch K; O'Sullivan G
Br J Psychiatry; 1994 May; 164(5):647-52. PubMed ID: 7921715
[TBL] [Abstract][Full Text] [Related]
27. DSM-III-R Axis I and II disorders in agoraphobic patients with and without panic disorder.
Hoffart A; Thornes K; Hedley LM; Strand J
Acta Psychiatr Scand; 1994 Mar; 89(3):186-91. PubMed ID: 8178677
[TBL] [Abstract][Full Text] [Related]
28. Specific side effects of long-term imipramine management of panic disorder.
Mavissakalian M; Perel J; Guo S
J Clin Psychopharmacol; 2002 Apr; 22(2):155-61. PubMed ID: 11910260
[TBL] [Abstract][Full Text] [Related]
29. Korean panic disorder severity scale: construct validity by confirmatory factor analysis.
Lim YJ; Yu BH; Kim JH
Depress Anxiety; 2007; 24(2):95-102. PubMed ID: 16845647
[TBL] [Abstract][Full Text] [Related]
30. Alpidem in the treatment of panic disorder.
Schneier FR; Carrasco JL; Hollander E; Campeas R; Fallon B; Saoud JB; Feerick J; Liebowitz MR
J Clin Psychopharmacol; 1993 Apr; 13(2):150-3. PubMed ID: 8096527
[TBL] [Abstract][Full Text] [Related]
31. Personality traits in early phases of panic disorder: implications on the presence of agoraphobia, clinical severity and short-term outcome.
Carrera M; Herrán A; Ramírez ML; Ayestarán A; Sierra-Biddle D; Hoyuela F; Rodríguez-Cabo B; Vázquez-Barquero JL
Acta Psychiatr Scand; 2006 Dec; 114(6):417-25. PubMed ID: 17087790
[TBL] [Abstract][Full Text] [Related]
32. Pre-treatment predictors of treatment outcome in panic disorder and agoraphobia treated with alprazolam and exposure.
Başoğlu M; Marks IM; Swinson RP; Noshirvani H; O'Sullivan G; Kuch K
J Affect Disord; 1994 Feb; 30(2):123-32. PubMed ID: 7911132
[TBL] [Abstract][Full Text] [Related]
33. Higher postdexamethasone serum cortisol levels in agoraphobic than in nonagoraphobic panic disorder patients.
Westberg P; Modigh K; Lisjö P; Eriksson E
Biol Psychiatry; 1991 Aug; 30(3):247-56. PubMed ID: 1912116
[TBL] [Abstract][Full Text] [Related]
34. [Validation of the French version of the situational characteristics questionnaire in the measurement of space and motion discomfort].
Vaillancourt L; Bélanger C; Léger-Bélanger MP; Jacob RG
Encephale; 2012 Jun; 38(3):248-56. PubMed ID: 22726413
[TBL] [Abstract][Full Text] [Related]
35. DSM-III-R Axis I and II disorders in agoraphobic inpatients with and without panic disorder before and after psychosocial treatment.
Hoffart A; Thornes K; Hedley LM
Psychiatry Res; 1995 Jan; 56(1):1-9. PubMed ID: 7792336
[TBL] [Abstract][Full Text] [Related]
36. Exposure reduced agoraphobia but not panic, and cognitive therapy reduced panic but not agoraphobia.
van den Hout M; Arntz A; Hoekstra R
Behav Res Ther; 1994 May; 32(4):447-51. PubMed ID: 7910732
[TBL] [Abstract][Full Text] [Related]
37. Do antidepressants selectively suppress spontaneous (unexpected) panic attacks? A replication.
Uhlenhuth EH; Matuzas W; Warner TD; Paine S; Lydiard RB; Pollack MH
J Clin Psychopharmacol; 2000 Dec; 20(6):622-7. PubMed ID: 11106133
[TBL] [Abstract][Full Text] [Related]
38. Imipramine vs. sertraline in panic disorder: 24-week treatment completers.
Mavissakalian MR
Ann Clin Psychiatry; 2003; 15(3-4):171-80. PubMed ID: 14971862
[TBL] [Abstract][Full Text] [Related]
39. Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia.
Mavissakalian M; Perel JM
Arch Gen Psychiatry; 1992 Apr; 49(4):318-23. PubMed ID: 1558466
[TBL] [Abstract][Full Text] [Related]
40. A controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatients.
Ravaris CL; Friedman MJ; Hauri PJ; McHugo GJ
J Clin Psychopharmacol; 1991 Dec; 11(6):344-50. PubMed ID: 1770152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
